Cabazitaxel

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Penile Neoplasm

Conditions

Penile Neoplasm

Trial Timeline

Dec 5, 2014 → Nov 16, 2016

NCT ID

NCT03114254

About Cabazitaxel

Cabazitaxel is a phase 2 stage product being developed by Sanofi for Penile Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT03114254. Target conditions include Penile Neoplasm.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01981668	Phase 1	Withdrawn	—	—	Prostatic Neoplasms
NCT03050866	Phase 2	UNKNOWN	Feb 21, 2017	Aug 19, 2022	Circulating Tumor Cell
NCT02621190	Phase 2	Withdrawn	Feb 1, 2016	Jun 1, 2019	Prostatic Neoplasms
NCT02512458	Phase 2	Completed	Oct 29, 2015	Dec 27, 2019	Bone Metastatic Prostate Cancer
NCT02166658	Phase 2	Terminated	Aug 1, 2015	Jan 18, 2018	Breast Cancer
NCT02478502	Phase 2	Terminated	Jun 1, 2015	Dec 31, 2022	Testicular Cancer
NCT03114254	Phase 2	Completed	Dec 5, 2014	Nov 16, 2016	Penile Neoplasm
NCT01913652	Phase 2	Completed	Oct 1, 2014	Dec 1, 2020	Dedifferentiated Liposarcoma
NCT02115165	Phase 2	Completed	Jul 27, 2014	Apr 24, 2023	Non-seminomatous Germ-cell Tumors
NCT01952223	Phase 3	Active	Dec 1, 2013	Jul 1, 2041	Adenocarcinoma of Prostate
NCT01913067	Phase 2	Withdrawn	Sep 1, 2013	Sep 1, 2016	Brain Metastasis
NCT01740570	Phase 1/2	Withdrawn	Apr 1, 2013	—	Brain Cancer
NCT01747239	Phase 2	Terminated	Jan 1, 2013	Jul 1, 2014	Ovarian Cancer
NCT01668459	Phase 2/3	Completed	Jan 1, 2013	Nov 1, 2017	Transitional Cell Carcinoma
NCT01757171	Phase 2	Completed	Dec 1, 2012	Jun 1, 2017	Gastric Adenocarcinoma
NCT01693549	Phase 2	Completed	Sep 1, 2012	Jul 20, 2017	Breast Cancer
NCT01254279	Phase 3	Completed	Dec 1, 2010	Dec 1, 2014	Prostate Cancer Metastatic

Competing Products

8 competing products in Penile Neoplasm

See all competitors

Product	Company	Stage	Hype Score
Avelumab + enfortumab vedotin	Astellas Pharma	Phase 2	42
Pembrolizumab + Standard of care therapy	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	27
Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab	Roche	Phase 2	35
Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires	Pfizer	Pre-clinical	18
Dacomitinib	Pfizer	Phase 2	35
Avelumab	Pfizer	Phase 2	31
Retifanlimab	Incyte	Phase 2	32